For research use only. Not for therapeutic Use.
Centhaquine (Centhaquin; PMZ-2010) is a novel agent has the potential for treatment of haemorrhagic shock. Centhaquine (Centhaquin; PMZ-2010) can augment cardiac output, reduce systemic vascular resistance in haemorrhagic models[1][2].
Centhaquine (Centhaquin) (intravenous injection, 0.01-1.0 mg/kg; intraduodenal administration 1.0-2.5 mg/kg) lowers the blood pressure and reduced the heart rate of anaesthetized and unanaesthetized (decerebrate) cat in a dose-dependent manner[1].
Centhaquine (Centhaquin) (intravertebral arterial injection; 5-10 μg) or by topical application to the exposed ventral surface of medulla or floor of the fourth ventricle causes hypotension and bradycardia as well as reduced the excitability of the vasomotor loci[1].
Centhaquine (Centhaquin;PMZ-2010) (intravenous administration; 0.015mg/kg) can attenuate the deleterious effects of catecholamines, improving both the macro- and microcirculation during CPR[2].
| Catalog Number | I005935 |
| CAS Number | 57961-90-7 |
| Synonyms | 2-[2-[4-(3-methylphenyl)piperazin-1-yl]ethyl]quinoline |
| Molecular Formula | C22H25N3 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H25N3/c1-18-5-4-7-21(17-18)25-15-13-24(14-16-25)12-11-20-10-9-19-6-2-3-8-22(19)23-20/h2-10,17H,11-16H2,1H3 |
| InChIKey | UJNWGFBJUHIJKK-UHFFFAOYSA-N |
| SMILES | CC1=CC(=CC=C1)N2CCN(CC2)CCC3=NC4=CC=CC=C4C=C3 |
| Reference | [1]. Srimal RC,et al. Pharmacological studies on 2-(2-(4-(3-methylphenyl)-1-piperazinyl)ethyl) quinoline (centhaquin). I. Hypotensive activity.Pharmacol Res. 1990 May-Jun;22(3):319-29. [2]. Papalexopoulou K, et al. Centhaquin Effects in a Swine Model of Ventricular Fibrillation: Centhaquin and Cardiac Arrest.Heart Lung Circ. 2017 Aug;26(8):856-863. |
